Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lokelma vs RAASi/MRA adjustment for hyperkalemia in CKD
2024-517631-43-00Phase 3Authorised
- Sponsor
- Instituto de Investigación Sanitaria Hospital Clínico San Carlos
- Start
- Sep 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hyperkalemia comparing Lokelma with Standard of care (2 arms). Primary endpoint: Serum potassium control at 90 days. Planned start Sep 2024; status: authorised.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2024-517631-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517631-43-00.